Obtain approval from the NMPA and ethics committee (Institutional Review Board - IRB) before initiating any clinical trial activities. The approval process ensures that the trial protocol meets ethical standards and regulatory requirements.

The regulatory requirements for NMPA registration (National Medical Products Administration) for invasive blood pressure monitoring devices in China encompass several key aspects to ensure safety, efficacy, and quality standards are met.

The validity period of NMPA registration for invasive blood pressure monitoring devices in China is typically 5 years. This registration period aligns with the regulatory requirement for most medical devices under the NMPA's oversight.

The technical file requirements for NMPA registration (National Medical Products Administration) for invasive blood pressure monitoring devices in China typically include comprehensive documentation to demonstrate compliance with regulatory standards and ensure device safety, efficacy, and performance.

The clinical evaluation for NMPA registration (National Medical Products Administration) for invasive blood pressure monitoring devices in China involves a systematic assessment to demonstrate the safety, performance, and clinical benefits of the device.

Applying for NMPA registration (National Medical Products Administration) for invasive blood pressure monitoring devices in China involves several structured steps to ensure compliance with regulatory requirements.

The purpose of an equivalency assessment is to streamline the registration process for medical devices by leveraging existing approvals or certifications from recognized regulatory authorities. This can help reduce duplication of efforts and expedite market access.

Determine the classification of your invasive blood pressure monitoring device according to Chinese regulations (e.g., Class II or III). Classification is based on factors such as intended use, technology, and potential risks.